Healy D J, Meador-Woodruff J H
Mental Health Research Institute and Department of Psychiatry, University of Michigan, Ann Arbor, Michigan 48109-0720, USA.
Synapse. 2000 Dec 1;38(3):294-304. doi: 10.1002/1098-2396(20001201)38:3<294::AID-SYN8>3.0.CO;2-U.
Electrophysiological data suggest that alterations in the function of one glutamate receptor subtype may affect the function of other subtypes. Further, previous studies have demonstrated that NMDA receptor antagonists affect NMDA and kainate receptor expression in rat hippocampus. In order to address the mutual regulation of NMDA, AMPA, and kainate receptor expression in rat hippocampus, we conducted two experiments examining the effects of NMDA and non-NMDA glutamate receptor modulators on NMDA, AMPA, and kainate receptor expression using in situ hybridization and receptor autoradiography. NMDA receptor expression was preferentially affected by systemic treatments, as all drugs significantly altered [(3)H]MK-801 binding, and several drugs increased [(3)H]ifenprodil binding. GYKI52466 and aniracetam treatments resulted in changes in both [(3)H]ifenprodil binding and NR2B mRNA levels, consistent with the association of this subunit and binding site in vitro. There were more modest effects on AMPA and kainate receptor expression, even by direct antagonists. Together, these data suggest that ionotropic glutamate receptors interact at the level of expression. These data also suggest that drug regimens targeting one ionotropic glutamate receptor subtype may indirectly affect other subtypes, potentially producing unwanted side effects.
电生理数据表明,一种谷氨酸受体亚型功能的改变可能会影响其他亚型的功能。此外,先前的研究表明,NMDA受体拮抗剂会影响大鼠海马体中NMDA和海人酸受体的表达。为了研究大鼠海马体中NMDA、AMPA和海人酸受体表达的相互调节作用,我们进行了两项实验,采用原位杂交和受体放射自显影技术,检测NMDA和非NMDA谷氨酸受体调节剂对NMDA、AMPA和海人酸受体表达的影响。全身给药优先影响NMDA受体的表达,因为所有药物均显著改变了[(3)H]MK-801结合,且几种药物增加了[(3)H]ifenprodil结合。GYKI52466和阿尼西坦治疗导致[(3)H]ifenprodil结合和NR2B mRNA水平均发生变化,这与该亚基和结合位点在体外的关联一致。即使是直接拮抗剂,对AMPA和海人酸受体表达的影响也较小。总之,这些数据表明离子型谷氨酸受体在表达水平上相互作用。这些数据还表明,针对一种离子型谷氨酸受体亚型的药物治疗方案可能会间接影响其他亚型,从而可能产生不良副作用。